Stephan Bohl

725 total citations
16 papers, 329 citations indexed

About

Stephan Bohl is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Stephan Bohl has authored 16 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Hematology and 3 papers in Oncology. Recurrent topics in Stephan Bohl's work include Acute Myeloid Leukemia Research (6 papers), Protein Degradation and Inhibitors (6 papers) and Multiple Myeloma Research and Treatments (4 papers). Stephan Bohl is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Protein Degradation and Inhibitors (6 papers) and Multiple Myeloma Research and Treatments (4 papers). Stephan Bohl collaborates with scholars based in Germany, United States and Austria. Stephan Bohl's co-authors include Lars Bullinger, Frank G. Rücker, Florian Kuchenbauer, Martin Bommer, Hartmut Döhner, S. von Harsdorf, A. MAUREEN ROUHI, Donald Bunjes, Andreas Pircher and Wolfgang Hilbe and has published in prestigious journals such as Nature Communications, Blood and International Journal of Molecular Sciences.

In The Last Decade

Stephan Bohl

16 papers receiving 325 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephan Bohl Germany 8 176 159 89 56 39 16 329
Kristina Sohlbach Germany 9 152 0.9× 132 0.8× 101 1.1× 101 1.8× 63 1.6× 17 347
Kiyoshi Okazuka Japan 11 160 0.9× 180 1.1× 87 1.0× 108 1.9× 39 1.0× 36 340
M Martín-Ayuso Spain 9 110 0.6× 164 1.0× 127 1.4× 66 1.2× 54 1.4× 10 280
J. Maciejewski United States 7 180 1.0× 259 1.6× 34 0.4× 30 0.5× 107 2.7× 10 345
Elena Sebastián Spain 9 55 0.3× 87 0.5× 92 1.0× 82 1.5× 63 1.6× 34 260
Hollie Devine United States 7 257 1.5× 343 2.2× 131 1.5× 146 2.6× 50 1.3× 9 524
Raquel Jiménez Spain 6 189 1.1× 327 2.1× 63 0.7× 171 3.1× 66 1.7× 14 381
David Stroncek United States 4 87 0.5× 59 0.4× 99 1.1× 83 1.5× 56 1.4× 11 263
Haerim Chung South Korea 12 123 0.7× 122 0.8× 73 0.8× 93 1.7× 62 1.6× 46 352
Monika J. Stankiewicz United States 7 171 1.0× 171 1.1× 63 0.7× 28 0.5× 90 2.3× 11 336

Countries citing papers authored by Stephan Bohl

Since Specialization
Citations

This map shows the geographic impact of Stephan Bohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Bohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Bohl more than expected).

Fields of papers citing papers by Stephan Bohl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephan Bohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Bohl. The network helps show where Stephan Bohl may publish in the future.

Co-authorship network of co-authors of Stephan Bohl

This figure shows the co-authorship network connecting the top 25 collaborators of Stephan Bohl. A scholar is included among the top collaborators of Stephan Bohl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephan Bohl. Stephan Bohl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Bohl, Stephan, et al.. (2023). Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma. Nature Communications. 14(1). 2897–2897. 11 indexed citations
2.
Ng, Yuen Lam Dora, Evelyn Ramberger, Stephan Bohl, et al.. (2022). Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nature Communications. 13(1). 1009–1009. 42 indexed citations
3.
Bohl, Stephan, Catharina Lahrmann, Linda Kessler, et al.. (2022). The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax. Blood. 140(Supplement 1). 6226–6227. 1 indexed citations
4.
Bohl, Stephan, Anna Dolnik, Martin Szyska, et al.. (2021). Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. Blood Advances. 5(9). 2391–2402. 16 indexed citations
5.
Ng, Yuen Lam Dora, Stephan Bohl, Evelyn Ramberger, et al.. (2019). Quantitative Proteomic Analysis of Relapsed Multiple Myeloma Identifies CDK6 Upregulation As a Potential Targetable Resistance Mechanism for Lenalidomide. Blood. 134(Supplement_1). 2567–2567. 1 indexed citations
6.
Bohl, Stephan, Lars Bullinger, & Frank G. Rücker. (2019). New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise. International Journal of Molecular Sciences. 20(8). 1983–1983. 67 indexed citations
7.
Bommer, Martin, et al.. (2018). The Differential Diagnosis and Treatment of Thrombotic Microangiopathies. Deutsches Ärzteblatt international. 115(19). 327–334. 29 indexed citations
8.
Bohl, Stephan, Lars Bullinger, & Frank G. Rücker. (2018). Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Review of Hematology. 11(5). 361–371. 64 indexed citations
9.
Bohl, Stephan, Florian Kuchenbauer, S. von Harsdorf, et al.. (2017). Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy. Biology of Blood and Marrow Transplantation. 23(12). 2172–2177. 55 indexed citations
10.
Bohl, Stephan, Anna Dolnik, Thomas E. Jensen, et al.. (2017). Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes. Leukemia & lymphoma. 58(9). 2264–2267. 6 indexed citations
11.
Bohl, Stephan, Stephanie von Harsdorf, Medhanie Mulaw, et al.. (2016). Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT. Bone Marrow Transplantation. 51(7). 994–996. 4 indexed citations
12.
Zizer, Eugen, Stephan Bohl, Dietmar M. Klass, et al.. (2016). High Prognostic Value of Mini-Laparoscopy for Advanced Liver Disease-Related Complications in Patients with HCV Infection. Digestion. 94(2). 114–122. 1 indexed citations
13.
Bohl, Stephan, et al.. (2016). Nivolumab Induces Remission in High- PD-L1 Expressing Aggressive B-Non Hodgkin Lymphoma: A Single Center Experience. Blood. 128(22). 1865–1865. 4 indexed citations
14.
Bohl, Stephan, Stephanie von Harsdorf, Verena Wais, et al.. (2016). Eculizumab Therapy of Adult TA-TMA: A High Response Rate Is Associated with a High Infection-Related Mortality. Blood. 128(22). 2255–2255. 5 indexed citations
15.
Bohl, Stephan, Rainer Claus, Anna Dolnik, et al.. (2013). Decitabine Response Associated Gene Expression Patterns In Acute Myeloid Leukemia (AML). Blood. 122(21). 3756–3756. 7 indexed citations
16.
Bohl, Stephan, Andreas Pircher, & Wolfgang Hilbe. (2011). Cancer Stem Cells: Characteristics and Their Potential Role for New Therapeutic Strategies. Onkologie. 34(5). 269–274. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kristina Sohlbach Breakdown of academic impact, for papers by Kiyoshi Okazuka Breakdown of academic impact, for papers by M Martín-Ayuso Breakdown of academic impact, for papers by J. Maciejewski Breakdown of academic impact, for papers by Elena Sebastián Breakdown of academic impact, for papers by Hollie Devine Breakdown of academic impact, for papers by Raquel Jiménez Breakdown of academic impact, for papers by David Stroncek Breakdown of academic impact, for papers by Haerim Chung Breakdown of academic impact, for papers by Monika J. Stankiewicz
Rankless by CCL
2026